New York, USA – July 27, 2021 – Histobiolab, the mature division of Creative Bioarray, is dedicated to providing a wide range of high quality human and animal cells, cell culture related services and histology services in order to accelerate life science research and biology research. Recently, Histobiolab announced the release of its ISH services to support its application in clinical cytogenetics, tumor biology, gene mapping and chromosome evolution research.
ISH is different from immunohistochemistry, which usually locates proteins in tissue sections. ISH can be performed on a variety of targets, including intracellular RNA, DNA from metaphase chromosome preparations obtained from mitotic cells, or DNA from interphase nuclei of non-mitotic cells. ISH not only has the advantage of detecting under the background of morphology, but also is favored by people because of its high sensitivity to nucleic acid detection. Histobiolab’s experienced team uses brightfield and fluorescence techniques in tissues and cells to provide ISH services. Multiple ISH can also be used to locate two or more probes in the same sample, imaging the entire slide, and ISH quantification.
Histobiolab’s in situ hybridization probes include double-stranded DNA (dsDNA) probes, single-stranded DNA (ssDNA) probes, RNA probes (ribosome probes), synthetic oligonucleotides (PNA, LNA). Compared with other methods, in situ hybridization workflow offered by Histobiolab has been simplified, and it takes less time to process samples and can be applied in the field of microbiology, pathology, developmental biology, karyotyping and phylogenetic analysis, physical mapping.
Creative Bioarray is capable to provide the most advanced molecular pathology services on multiple high-throughput testing platforms, including the preparation of DNA, RNA and protein from a large number of samples for molecular detection, massively parallel sequencing, Sanger sequencing, gene expression analysis and quantification polymerase chain reaction.
In drug discovery and preclinical safety assessment, changes in cell morphology are often accompanied by changes in DNA, RNA or protein molecules. Further understanding of these molecular changes will help to understand target distribution, pharmacodynamics, and elucidate pharmacological and/or toxicological mechanisms. In addition, there is an increasing demand for information on tumor subtypes, prognosis, treatment response, and molecular therapy targets. These needs are increasingly being covered by molecular pathology and require more extensive methods. Except for ISH services, Creative Bioarray also develops PCR and quantitative PCR services, chromosome analysis services and next generation sequencing (NGS) services.
“Our team combines the history of molecular biology and histopathology, linking gene expression with tissue morphology in normal tissues and therapeutic disease models to provide you with valuable functional genomics information.” said Hannah Cole, the marketing director of Creative Bioarray, she also added, “In addition, we are proficient in histopathology and immunocytochemistry methods, provides a full range of services in sample preparation, imaging and image analysis, and provides consulting for ongoing or future research projects.”
As a mature division of Creative Bioarray, Histobiolab definitely will be the ideal and reliable innovation partner in research endeavors. With the support of professional scientists and years of experience, We are capable to provide a knowledgeable, collaborative and flexible service to our clients so as to accelerated drug development and improved research quality for worldwide projects.